|
?:abstract
|
-
Introduction Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020 The complexity of handling multiple myeloma (MM) has increased substantially during this pandemic The objective of this review is to know the current recommendation to manage MM in the COVID-19 era Methods Electronic databases, including PubMed central and PubMed, were used to conduct a literature search It was conducted on May 18, 2020, using the keywords multiple myeloma AND COVID-19 AND Prevalence OR Impact OR treatment OR prophylactic The included articles were review articles, recommendations, case reports or series, or population-based studies (cross-sectional, cohort, case-control, or interventional), and full-text if available Results A total of 124 articles were identified through the search strategy The two reviewers screened titles and abstracts of all articles Most articles were excluded because of ineligible to the criteria Ultimately, 18 articles were included in the final evaluation MM patients might have higher risk to become severe COVID-19 if they got infected due to their immunocompromised condition Due to the pandemic, precise treatment priorities should be made by considering its benefit and the risk of MM progression For the young, especially healthy patients, the most effective therapy should be offered and tailored to the patient\'s goal Several MM societies have published the recommendation regarding the special stage of MM Conclusion Myeloma societies in the world have released recommendations related to the management of myeloma patients However, there is scarce of evidence to do the recommendation
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}